ArticleTherapeutic innovation & regulatory science2026
Association Between FDA Drug Recall Classification and Product-Related Characteristics.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study examined associations between FDA drug recall classification (Class I-III) and selected product-related characteristics using publicly available recall data.
methodsA secondary analysis of 13,248 FDA drug recalls issued from 2015 to 2024 was conducted. Data on recall classification, recall cause, dosage form, therapeutic category, and geographic origin were extracted from publicly available FDA databases. Descriptive statistics were used to summarize recall distributions. Pearson's chi-square tests assessed associations between recall classification and categorical variables, and Cramér's V was used to quantify the magnitude of association.
resultsSignificant associations were identified between recall classification and recall cause (χ
conclusionRecall classification was significantly associated with multiple product-related characteristics, particularly recall cause. While these findings reflect statistical associations rather than causal relationships, they identify recurring patterns within FDA recall data that may inform risk-based regulatory surveillance and pharmaceutical quality management activities. Because exposure-adjusted denominator data were unavailable, the findings should be interpreted as patterns within recalled products rather than measures of comparative product risk.
Indexed as
Identifiers
42436311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.